Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05370430 · ClinicalTrials.gov registry record · Phase 1
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
A Phase 1 study of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, sponsored by PeproMene Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 6
- Study locations
NCT05370430 is a Phase 1 study of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma that is actively recruiting participants, run by PeproMene Bio. The registered enrollment target is 36 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT05370430, a Phase 1 study of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, is actively recruiting participants, sponsored by PeproMene Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 6
- Study locations
Study Summary
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Conditions Studied
Interventions
- BIOLOGICAL BAFFR-CAR T cells
Study Locations (6)
California
- City of Hope Medical Center - Duarte
- Stanford University - Stanford
Kansas
- University of Kansas Hospital - Kansas City
Minnesota
- University of Minnesota - Minneapolis
North Carolina
- Atrium Health Levine Cancer Institute - Morehead - Charlotte
Washington
- Providence Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2028-06-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05370430
The ClinicalTrials.gov registry entry for NCT05370430 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PeproMene Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which BAFFR-CAR T cells is the first listed.
NCT05370430 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Kansas, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05370430 about?
NCT05370430 is a clinical study titled "BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL". A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
What is the current status of trial NCT05370430?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-06-13. Estimated completion is 2028-06-13.
What conditions does trial NCT05370430 study?
This clinical trial studies the following conditions: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT05370430?
The interventions under investigation include: BAFFR-CAR T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05370430?
This trial is sponsored by PeproMene Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05370430 being conducted?
This trial has 6 study locations across California, Kansas, Minnesota, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.